Expertise in
1
conditions

Dr. Jeremie Calais

Nuclear Medicine
200 Medical Plaza Suite B114, 
Los Angeles, CA 
Expertise in
1
conditions
200 Medical Plaza Suite B114, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeremie Calais is a Nuclear Medicine provider in Los Angeles, California. Dr. Calais is highly rated in 1 condition, according to our data. His top areas of expertise are Prostatectomy and Lymphadenectomy.

His clinical research consists of co-authoring 208 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Nuclear Medicine
Licenses
Nuclear Imaging & Therapy in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

200 Medical Plaza Suite B114, Los Angeles, CA 90095

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Evaluation of 68Ga-PSMA-11 PET Guided Prostate Biopsy in Men With Suspicion of Clinically Significant Prostate Cancer and Prior Negative/Inconclusive Biopsy: A Prospective Exploratory Study
Evaluation of 68Ga-PSMA-11 PET Guided Prostate Biopsy in Men With Suspicion of Clinically Significant Prostate Cancer and Prior Negative/Inconclusive Biopsy: A Prospective Exploratory Study
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Procedure, Other
Study Phase: Early Phase 1
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Radiation, Drug, Procedure
Study Drug: Gallium Ga 68 FAPi-46
Study Phase: Phase 1
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Sarcoma: An Exploratory Biodistribution Study With Histopathology Validation
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Sarcoma: An Exploratory Biodistribution Study With Histopathology Validation
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Radiation, Drug, Procedure
Study Drug: Gallium Ga 68 FAPi-46
Study Phase: Early Phase 1
PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46 in Patients With Non-Prostate Cancers: An Exploratory Biodistribution Study With Histopathology Validation
PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46 in Patients With Non-Prostate Cancers: An Exploratory Biodistribution Study With Histopathology Validation
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Radiation, Procedure
Study Phase: Early Phase 1
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Prostate Cancer: A Prospective Exploratory Biodistribution Study With Histopathology Validation
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Prostate Cancer: A Prospective Exploratory Biodistribution Study With Histopathology Validation
Enrollment Status: Active_not_recruiting
Publish Date: July 15, 2025
Intervention Type: Other, Procedure
Study Drug: Ga-68 FAPi-46
Study Phase: Phase 1
Phase III Randomized Multicenter Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]
Phase III Randomized Multicenter Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2025
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
Phase 3 Randomized Trial Of PSMA PET Prior to Definitive Radiation Therapy for Unfavorable Intermediate-Risk or High-Risk Prostate Cancer [PSMA dRT]
Phase 3 Randomized Trial Of PSMA PET Prior to Definitive Radiation Therapy for Unfavorable Intermediate-Risk or High-Risk Prostate Cancer [PSMA dRT]
Enrollment Status: Terminated
Publish Date: January 17, 2023
Intervention Type: Radiation, Procedure, Other
Study Phase: Phase 3
Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT With 99mTc-MDP Bone Scan and CT for Detection of M1b Disease in Prostate Cancer Patients With Biochemical Progression During ADT
Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT With 99mTc-MDP Bone Scan and CT for Detection of M1b Disease in Prostate Cancer Patients With Biochemical Progression During ADT
Enrollment Status: Terminated
Publish Date: October 21, 2022
Intervention Type: Procedure, Other
Study Phase: Phase 2
Effects of Novel Androgen Receptor Signaling Inhibitors on PSMA PET Signal Intensity in Patients With Castrate-Resistant Prostate Cancer: A Prospective Exploratory Study
Effects of Novel Androgen Receptor Signaling Inhibitors on PSMA PET Signal Intensity in Patients With Castrate-Resistant Prostate Cancer: A Prospective Exploratory Study
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Procedure, Drug
Study Drug: Ga-68 Gozetotide
Study Phase: Phase 1
Impact of 68GA-PSMA-11 PET/CT on Initial and Subsequent Treatment Strategies of Patients With Prostate Cancer
Impact of 68GA-PSMA-11 PET/CT on Initial and Subsequent Treatment Strategies of Patients With Prostate Cancer
Enrollment Status: Completed
Publish Date: September 30, 2021
Intervention Type: Other, Procedure, Drug
Study Drug: Gallium Ga 68-Labeled PSMA-11
Study Phase: Phase 2
Expanded Access Protocol of 68Ga-PSMA-11 for Prostate Cancer PET Imaging
Expanded Access Protocol of 68Ga-PSMA-11 for Prostate Cancer PET Imaging
Enrollment Status: Approved_for_marketing
Publish Date: June 24, 2021
Intervention Type: Diagnostic test
Evaluation by 68Ga-PSMA-11 PET Imaging of Monosodium Glutamate as a Potential Agent for Salivary Gland Protection Under PSMA-targeted Alpha-therapy: a Randomized Pilot Imaging Research Study
Evaluation by 68Ga-PSMA-11 PET Imaging of Monosodium Glutamate as a Potential Agent for Salivary Gland Protection Under PSMA-targeted Alpha-therapy: a Randomized Pilot Imaging Research Study
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Dietary supplement, Procedure, Drug
Study Phase: Early Phase 1
View 12 Less Clinical Trials

208 Total Publications

From Nuclear Medicine Specialist to Cancer Center Director: Jeremie Calais Talks with Pierre Vera about Leading Through Change in Nuclear Medicine.
From Nuclear Medicine Specialist to Cancer Center Director: Jeremie Calais Talks with Pierre Vera about Leading Through Change in Nuclear Medicine.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 11, 2025
Similar Doctors
Expertise in
20
conditions
Dr. Jason S. Bradfield
Cardiac Electrophysiology | Cardiology | Nuclear Medicine
Expertise in
20
conditions
Dr. Jason S. Bradfield
Cardiac Electrophysiology | Cardiology | Nuclear Medicine

The Regents Of The University Of California

200 Medical Plz, 
Los Angeles, CA 
 (0.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jason Bradfield is a Cardiac Electrophysiologist and a Cardiologist in Los Angeles, California. Dr. Bradfield is highly rated in 20 conditions, according to our data. His top areas of expertise are Ventricular Tachycardia, Arrhythmias, Ectopic Heartbeat, Cardiac Ablation, and Pacemaker Implantation.

Expertise in
28
conditions
Dr. Louise E. Thomson
Nuclear Medicine | Radiology
Expertise in
28
conditions
Dr. Louise E. Thomson
Nuclear Medicine | Radiology

Cedars-Sinai Medical Care Foundation

8700 Beverly Blvd, 
West Hollywood, CA 
 (3.6 miles away)
310-423-1447
Languages Spoken:
English
See accepted insurances

Louise Thomson is a Nuclear Medicine specialist and a Radiologist in West Hollywood, California. Dr. Thomson is highly rated in 28 conditions, according to our data. Her top areas of expertise are Neuroendocrine Tumor, Osteopenia, Melorheostosis, and Melorheostosis with Osteopoikilosis.

Expertise in
33
conditions
Dr. Victor A. Gabrielian
Nuclear Medicine | Cardiology
Expertise in
33
conditions
Dr. Victor A. Gabrielian
Nuclear Medicine | Cardiology

Foothill Cardiology Medical Group Inc

625 S Fair Oaks Ave, Suite 215, 
Pasadena, CA 
 (17.3 miles away)
626-793-4139
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Victor Gabrielian is a Nuclear Medicine specialist and a Cardiologist in Pasadena, California. Dr. Gabrielian is highly rated in 33 conditions, according to our data. His top areas of expertise are Mitral Valve Prolapse, Mitral Valve Regurgitation, Aortic Valve Stenosis, and Metabolic Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Calais's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile